Navigation Links
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
Date:11/4/2010

treated metastatic gastric cancer patients 128

SWOT analysis 128

Datamonitor drug assessment scorecard for Afinitor 129

Clinical and commercial attractiveness 130

If Phase III trial replicates Phase II survival, then Afinitor could become the standard of care in second-line metastatic gastric cancer 130

A relatively high rate of treatment discontinuation due to adverse events was seen in the Phase II study 130

Afinitor is set to be the first agent to reach the market for second-line metastatic gastric cancer 131

Afinitor shows applicability for use across the wider gastric cancer population 131

Design of the Phase III GRANITE-1 study may unnecessarily come under fire 131

Novartis's experience in the oncology market will prove crucial in ensuring Afinitor's success in gastric cancer 131

Satisfaction of unmet needs 131

Forecasts to 2019 132

Tykerb (lapatinib; GlaxoSmithKline) 133

Drug overview 133

Drug profile 133

Key historical events 134

Clinical trial data 135

Phase II results have shown minimal activity in first-line metastatic gastric cancer and failure to meet its primary endpoint of overall response rate 136

SWOT analysis 136

Datamonitor drug assessment scorecard for Tykerb 137

Clinical and commercial attractiveness 138

Minimal clinical data have been reported for Tykerb in gastric cancer, making it difficult to judge its clinical attractiveness 138

Dual inhibition of EGFR and HER-2 is a relatively new strategy in treatment of gastric cancer 139

Concerns exist over Tykerb's association with hepatotoxicity 139

Tykerb could provide strong competition to Herceptin in HER-2-positive gastric cancer 139

Satisfaction of unmet needs 139

Forecasts to 2019 140

Ramucirumab (IMC-1121B; Eli Lilly) 141

Drug overview 141

Drug profile 141

Key historical events 142

'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
2. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
5. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
6. Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
7. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
9. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
10. Reportlinker Adds Interventional Cardiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release third quarter 2014 financial results on Wednesday, ... The Company,s management will hold a conference call ... 2014, which is 8:30 p.m., Beijing Time on November ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 2010 Reportlinker.com announces that a new market research ... Toxicology and Pharmacology http://www.reportlinker.com/p0324751/Toxicology-and-Pharmacology.html ... Regulation; Technical, Political and Economic Challenges – key report ... are almost exclusively outsourced and the market is worth ...
... Nov. 3, 2010 Breast Cancer Action (BCA) learned today ... Lilly & Company via a billboard in Indianapolis have ... sick.  Tell them to stop" was rejected by every ... working within the guidelines of each billboard company contacted, ...
Cached Medicine Technology:Reportlinker Adds Toxicology and Pharmacology 2Reportlinker Adds Toxicology and Pharmacology 3Breast Cancer Message Barred in Eli Lilly's Hometown 2
(Date:10/31/2014)... October 31, 2014 Florida Air ... and girls in grades 6-12, is taking the ... sports injuries and concussions, becoming the first high ... ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) computerized ... NFL Player' lawsuit grabs the headlines, and the ...
(Date:10/31/2014)... 2014 FindSurrogateMother.com conveys a ... of life — building a family through surrogacy. The ... and donors with hopeful intended parents in turn generating ... It’s a collective aptitude of surrogate mothers, intended parents, ... fertility clinics that help provide these connections — and ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 In an effort ... patients, Dr. Majid Jamali announced he will soon offer orthodontics ... by the end of November. , To build upon ... Surgery of New York has become known for, Dr. Jamali ... degrees from such top learning institutions as UCLA, Stanford and ...
(Date:10/31/2014)... Triple Board Certified surgeon Dr. Jeffrey ... transform the appearance of military veteran Joseph Jones. ... Plastic and Reconstruction Surgery (AAFPRS) Faces of Honor program, ... hair Jones lost during an IED blast almost ten ... procedure, valued around $16,000, took Dr. Epstein over eight ...
(Date:10/31/2014)... 2014 Phoenix dentist , Dr. Christy, ... November. Whether patients simply need routine care or have a ... than now to get that necessary care. The right dental ... routine and even essential treatments due to financial concerns. Throughout ... on any treatments offered by the team at Christy Dental ...
Breaking Medicine News(10 mins):Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... that combines 2 medications , , SUNDAY, March 30 (HealthDay News) ... make sense of a trial showing that a drug can ... apparent benefit to people at high risk of heart attack ... well-known statin -- simvastatin -- with ezetimibe, which also lowers ...
... use with angioplasty following a heart attack, the anticoagulants ... measures within 90 minutes after the procedure, while patients ... a lower risk of major adverse cardiac events within ... to a JAMA study being released early online March ...
... risk and don,t increase mortality probability , , SUNDAY, March ... placed in diseased coronary arteries to keep them open, ... patients, new research shows. , In the largest study ... the drug in question retards the growth of arterial ...
... to Join Nation,s Largest RN ... Organization, ... registered nurses to have a stronger voice to speak,out for patients and ... to win union collective bargaining,rights., RNs at Cypress Fairbanks Medical Center ...
... deaths could be avoided with lifestyle changes, experts say, ... that could cut cancer deaths in half. , Well, ... American Cancer Society report that said as many as ... lifestyle changes, such as quitting smoking, maintaining a healthy ...
... mice was important protective mechanism, researchers say , , FRIDAY, March ... a critical role in protecting the heart during a heart ... It was already known that Gi increased activity in a ... helping the heart adapt to damage or if it actually ...
Cached Medicine News:Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3Health News:Key Protein Limits Damage of Heart Attack 2
World's first commercially available vacuum assisted biopsy device for MRI....
... you can perform stereotactic, ultrasound and MRI-guided ... of your office. Use the patented, FDA-cleared ... and more clinically advanced method of breast ... for the women who trust YOU.,9 Gauge ...
18" Penrose drains...
Offers a more constant suction profile than three-spring evacuators, resulting in the potential for improved tissue approximation and reduced risk of hematoma....
Medicine Products: